The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000438358
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
13/03/2026
Date registered
Help: Date registered
9/04/2026
Date last updated
Help: Date last updated
9/04/2026
Date data sharing statement initially provided
Help: Data sharing statement date
9/04/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
Clinical trial assessing the safety and feasibility of robotic urological procedures using the Toumai robot (SAFTOUro)
Scientific title
Clinical trial assessing the safety and feasibility of robotic urological procedures using the Toumai robot (SAFTOUro) for patients undergoing surgery for urological (prostate or renal) cancers
Additional trial identifiers [1] 316777 0
CH62/6/2026-010
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Prostate Cancer 341088 0
Kidney Cancer 341089 0
Condition category
Condition code
Cancer 337207 337207 0 0
Kidney
Cancer 337208 337208 0 0
Prostate
Surgery 337209 337209 0 0
Surgical techniques

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
The intervention in this study is the use of the Toumai® MT-1000 robotic surgical system to assist surgeons performing prostate or kidney cancer operations. The Toumai® MT-1000 is a next-generation robotic platform developed by Shanghai MicroPort MedBot and is designed to improve precision, instrument control, and visualisation during minimally invasive surgery. It provides a highly magnified 3D view and wrist-like robotic instruments that allow the surgeon to operate through small incisions while remaining in full control at all times. The Toumai® MT-1000 received approval from the Therapeutic Goods Administration (TGA) in May 2025 and is listed on the Australian Register of Therapeutic Goods (ARTG ID 487874) for use in urological, general, thoracic and gynaecological endoscopic surgery.
In this study, the type of surgery performed is the same as standard care; the study is evaluating the performance and safety of this newer robotic platform rather than introducing a different procedure. These operations typically take between two and four hours. All surgeons complete Toumai-specific training, including an online learning module, two hours of supervised dry-lab training, and at least five proctored cases led by an accredited national proctor before operating independently.
The study will observe how well the robotic system performs in real clinical settings by monitoring safety, and how patients recover after surgery, including their symptoms, quality of life and function in the months after their operation. Adherence to the intervention is monitored through review of medical records and peri-operative data forms completed after each operation, documenting use of the system, any technical issues, and whether the procedure followed the approved protocol.
Intervention code [1] 333463 0
Treatment: Surgery
Intervention code [2] 333527 0
Treatment: Devices
Description of the comparator or control
The findings of this study will be compared to a historical control group of already collected information from patients who previously had similar prostate or kidney cancer surgeries using the da Vinci robotic system within the SLHD. Historical comparator data will be sourced from the ROSE Study (X16-0294; 2019/ETH06594), PNUT Trial (X18-0389; 2019/ETH07303) and BEST Database (X16-0182; 2019/ETH08903) held by the SLHD at RPAH. Data collection periods used for matching are October 2016 to December 2025.
Control group
Historical

Outcomes
Primary outcome [1] 344729 0
Safety
Timepoint [1] 344729 0
At hospital discharge
Primary outcome [2] 344730 0
Feasibility
Timepoint [2] 344730 0
At the end of the procedure
Secondary outcome [1] 459326 0
Length of hospital stay
Timepoint [1] 459326 0
At hospital discharge
Secondary outcome [2] 459327 0
Estimated blood loss
Timepoint [2] 459327 0
At the end of the procedure
Secondary outcome [3] 459328 0
Total operative time
Timepoint [3] 459328 0
At the end of the procedure
Secondary outcome [4] 459329 0
Console time
Timepoint [4] 459329 0
At the end of the procedure
Secondary outcome [5] 459330 0
Docking time
Timepoint [5] 459330 0
At the end of the procedure
Secondary outcome [6] 459331 0
Blood transfusion
Timepoint [6] 459331 0
At the end of the procedure
Secondary outcome [7] 459332 0
Recurrence
Timepoint [7] 459332 0
3 months after surgery
Secondary outcome [8] 459333 0
Prostate-specific antigen (PSA) level (prostatectomy patients only)
Timepoint [8] 459333 0
3 months after surgery
Secondary outcome [9] 459334 0
Quality of life
Timepoint [9] 459334 0
Before surgery, 6 weeks after surgery and 6 months after surgery
Secondary outcome [10] 459335 0
Urinary and sexual function (prostatectomy patients only)
Timepoint [10] 459335 0
Before surgery, 3 months after surgery and 6 months after surgery
Secondary outcome [11] 459338 0
Continence
Timepoint [11] 459338 0
Before surgery, 3 months after surgery and 6 months after surgery
Secondary outcome [12] 459339 0
Clinician experience
Timepoint [12] 459339 0
At conclusion of the study
Secondary outcome [13] 459340 0
Learning curve
Timepoint [13] 459340 0
At the end of the procedure
Secondary outcome [14] 459341 0
In-hospital cost
Timepoint [14] 459341 0
At hospital discharge

Eligibility
Key inclusion criteria
Participants can take part in the study if they are adults aged 18 years or older and are scheduled to have prostate cancer surgery (radical prostatectomy) or kidney cancer surgery (partial nephrectomy or nephroureterectomy) at Concord Repatriation General Hospital. They must be considered suitable for robotic surgery by their treating surgeon and be able to understand the study information and provide written consent. Only patients booked for an elective (non-emergency) operation are eligible.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
People cannot take part in the study if they are unable to give informed consent or if their cancer or overall health makes robotic surgery unsafe. Patients will also be excluded if specific medical or tumour features mean that a robotic approach is not suitable. For kidney cancer surgery, people will be excluded if they have only one functioning kidney, very complex kidney tumours, evidence of cancer that has spread, severe kidney disease requiring dialysis, medical conditions that prevent the use of contrast imaging, or bleeding or clotting problems. Patients having emergency surgery or who do not meet the clinical requirements for robotic surgery will not be eligible to participate.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint/s
Safety
Statistical methods / analysis
The study will use simple descriptive statistics to summarise patient characteristics and surgical results, including safety and whether the operation could be completed robotically as planned. Operating time will be tracked across cases to understand the learning curve for the new robotic system. Where appropriate, results will be compared with existing data from patients who previously had similar surgery using the da Vinci robot. All analyses are exploratory because this is an early safety and feasibility study and is not designed to test effectiveness.

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW

Funding & Sponsors
Funding source category [1] 321374 0
Government body
Name [1] 321374 0
Sydney Local Health District
Country [1] 321374 0
Australia
Primary sponsor type
Government body
Name
Sydney Local Health District
Address
Country
Australia
Secondary sponsor category [1] 324117 0
None
Name [1] 324117 0
Address [1] 324117 0
Country [1] 324117 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319915 0
Sydney Local Health District HREC – Concord Repatriation General Hospital
Ethics committee address [1] 319915 0
Ethics committee country [1] 319915 0
Australia
Date submitted for ethics approval [1] 319915 0
30/01/2026
Approval date [1] 319915 0
13/03/2026
Ethics approval number [1] 319915 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 148806 0
A/Prof Ruban Thanigasalam
Address 148806 0
Inner West Urology 12 Mary Street Auburn 2144 NSW
Country 148806 0
Australia
Phone 148806 0
+61 2 9643 1223
Fax 148806 0
Email 148806 0
Contact person for public queries
Name 148807 0
Ruban Thanigasalam
Address 148807 0
Inner West Urology 12 Mary Street Auburn 2144 NSW
Country 148807 0
Australia
Phone 148807 0
+61 2 9643 1223
Fax 148807 0
Email 148807 0
Contact person for scientific queries
Name 148808 0
Ruban Thanigasalam
Address 148808 0
Inner West Urology 12 Mary Street Auburn 2144 NSW
Country 148808 0
Australia
Phone 148808 0
+61 2 9643 1223
Fax 148808 0
Email 148808 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires a scientifically sound proposal or protocol
• Requires approval by an ethics committee
• Requires a data sharing agreement between data requester and trial custodian or sponsor
What individual participant data might be shared?
• De-identified individual participant data:
• All outcomes data
• Published results
• Primary outcome(s)
• Safety data
What types of analyses could be done with individual participant data?
• Any type of analysis (i.e. no restrictions on data re-use)
When can requests for individual participant data be made (start and end dates)?
From:
At the end of the study
To:
Not yet decided
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: [email protected]

Are there extra considerations when requesting access to individual participant data?
Yes: Institutional data sharing policies at the discretion of the LHD



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.